Literature DB >> 20212418

Multi-targeted approach in the treatment of thyroid cancer.

B Zarebczan1, H Chen.   

Abstract

Thyroid cancer is the most common malignancy of the endocrine system. There are several variants, ranging from well-differentiated cancers, such as papillary carcinomas, to poorly differentiated types, which carry a worse prognosis. Many patients with well-differentiated thyroid cancers are cured by surgical intervention alone, while others require adjuvant therapy. For those patients with more aggressive tumors, such as metastatic and anaplastic thyroid cancers, surgery rarely offers a definitive cure and alternative treatment methods such as chemotherapy do not improve survival. Due to the difficulty in treating aggressive thyroid cancers, other novel therapies are needed. In this paper, we will review current strategies for managing the various types of thyroid carcinomas. We will also address many of the studied genetic pathways and new therapeutic drug targets for treating individual thyroid malignancies.

Entities:  

Mesh:

Year:  2010        PMID: 20212418      PMCID: PMC2901507     

Source DB:  PubMed          Journal:  Minerva Chir        ISSN: 0026-4733            Impact factor:   1.000


  81 in total

Review 1.  The renaissance of GSK3.

Authors:  P Cohen; S Frame
Journal:  Nat Rev Mol Cell Biol       Date:  2001-10       Impact factor: 94.444

Review 2.  Thyroid-hormone therapy and thyroid cancer: a reassessment.

Authors:  Bernadette Biondi; Sebastiano Filetti; Martin Schlumberger
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2005-11

Review 3.  The current management of thyroid cancer.

Authors:  R Udelsman; H Chen
Journal:  Adv Surg       Date:  1999

4.  A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer.

Authors:  Electron Kebebew; Miao Peng; Emily Reiff; Patrick Treseler; Kenneth A Woeber; Orlo H Clark; Francis S Greenspan; Sheila Lindsay; Quan-Yang Duh; Eugene Morita
Journal:  Surgery       Date:  2006-12       Impact factor: 3.982

5.  Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991.

Authors:  F D Gilliland; W C Hunt; D M Morris; C R Key
Journal:  Cancer       Date:  1997-02-01       Impact factor: 6.860

6.  Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A.

Authors:  Michael W Yeh; Jean-Philippe Rougier; Jin-Woo Park; Quan-Yang Duh; Mariwil Wong; Zena Werb; Orlo H Clark
Journal:  Endocr Relat Cancer       Date:  2006-12       Impact factor: 5.678

7.  Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium.

Authors:  L M Mulligan; D J Marsh; B G Robinson; I Schuffenecker; J Zedenius; C J Lips; R F Gagel; S I Takai; W W Noll; M Fink
Journal:  J Intern Med       Date:  1995-10       Impact factor: 8.989

Review 8.  Thyroid cancer nodal metastases: biologic significance and therapeutic considerations.

Authors:  S K Grebe; I D Hay
Journal:  Surg Oncol Clin N Am       Date:  1996-01       Impact factor: 3.495

9.  Multi-targeted approach in the treatment of thyroid cancer.

Authors:  Scott N Pinchot; Rebecca S Sippel; Herbert Chen
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

10.  Prognostic impact of EGF-receptor in papillary thyroid carcinoma.

Authors:  L A Akslen; A O Myking; H Salvesen; J E Varhaug
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

View more
  9 in total

Review 1.  Signaling mechanisms in neuroendocrine tumors as targets for therapy.

Authors:  Barbara Zarebczan; Herbert Chen
Journal:  Endocrinol Metab Clin North Am       Date:  2010-12       Impact factor: 4.741

2.  Antiproliferative effect of chrysin on anaplastic thyroid cancer.

Authors:  TramAnh Phan; Xiao-Min Yu; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  J Surg Res       Date:  2011-04-20       Impact factor: 2.192

3.  Hesperetin activates the Notch1 signaling cascade, causes apoptosis, and induces cellular differentiation in anaplastic thyroid cancer.

Authors:  Priyesh N Patel; Xiao-Min Yu; Renata Jaskula-Sztul; Herbert Chen
Journal:  Ann Surg Oncol       Date:  2014-01-14       Impact factor: 5.344

Review 4.  Advances in surgical therapy for thyroid cancer.

Authors:  Haggi Mazeh; Herbert Chen
Journal:  Nat Rev Endocrinol       Date:  2011-08-23       Impact factor: 43.330

Review 5.  New developments in the diagnosis and treatment of thyroid cancer.

Authors:  David F Schneider; Herbert Chen
Journal:  CA Cancer J Clin       Date:  2013-06-24       Impact factor: 508.702

6.  Identification and Validation of Novel Genes in Anaplastic Thyroid Carcinoma via Bioinformatics Analysis.

Authors:  Shengnan Wang; Jing Wu; Congcong Guo; Hongxia Shang; Jinming Yao; Lin Liao; Jianjun Dong
Journal:  Cancer Manag Res       Date:  2020-10-08       Impact factor: 3.989

7.  Clinicopathological characteristics of thyroid cancer in the federal state of Salzburg.

Authors:  Gundula Rendl; Margarida Rodrigues; Gregor Schweighofer-Zwink; Josef Hutter; Anton Hittmair; Barbara Zellinger; Cornelia Hauser-Kronberger; Christian Pirich
Journal:  Wien Klin Wochenschr       Date:  2017-05-10       Impact factor: 1.704

Review 8.  Molecular Functions of Thyroid Hormone Signaling in Regulation of Cancer Progression and Anti-Apoptosis.

Authors:  Yu-Chin Liu; Chau-Ting Yeh; Kwang-Huei Lin
Journal:  Int J Mol Sci       Date:  2019-10-09       Impact factor: 5.923

9.  The effect of chronic lymphocytic thyroiditis on patients with thyroid cancer.

Authors:  Yi Zhang; Xiao-Peng Ma; Fu-Sheng Deng; Zheng-Rong Liu; Hou-Qing Wei; Xi-Hong Wang; Hao Chen
Journal:  World J Surg Oncol       Date:  2014-09-01       Impact factor: 2.754

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.